Which of the following drugs is not a part of the ‘Triple Therapy’ immunosuppression for post-renal transplant patients?
## Core Concept
The 'Triple Therapy' immunosuppression regimen for post-renal transplant patients typically involves a combination of medications to prevent rejection. This regimen usually consists of a **calcineurin inhibitor** (e.g., cyclosporine or tacrolimus), an **antiproliferative agent** (e.g., mycophenolate mofetil or azathioprine), and a **corticosteroid** (e.g., prednisone).
## Why the Correct Answer is Right
The correct answer, , is not a part of the traditional 'Triple Therapy' regimen because it is an **mTOR inhibitor** (e.g., sirolimus). While mTOR inhibitors are used in immunosuppression protocols, they are often used as part of a quadruple therapy or in place of one of the components of the triple therapy, not typically as a standard component of the triple therapy.
## Why Each Wrong Option is Incorrect
* **Option A:** is a calcineurin inhibitor, which is a standard component of the triple therapy regimen.
* **Option B:** is an antiproliferative agent, another standard component of the triple therapy regimen.
* **Option D:** is a corticosteroid, which is also a standard component of the triple therapy regimen.
## Clinical Pearl / High-Yield Fact
A key point to remember is that the goal of immunosuppression in post-renal transplant patients is to balance the risk of rejection with the risk of adverse effects. The 'Triple Therapy' regimen is often tailored to the individual patient, and alternatives or additional agents may be used based on specific clinical scenarios and side effect profiles.
## Correct Answer Line
**Correct Answer: .**